Akebia expands anemia drug collaboration with Otsuka
The companies have signed an agreement in December 2016 to jointly develop and commercialize the drug, called vadadustat. The deal called for Akebia to receive $265m in committed funds,
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).